Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo by NORRBY, KLAS & NORDENHEM, ARVID
Dalteparin, a low-molecular-weight heparin,
promotes angiogenesis mediated by heparin-binding
VEGF-A in vivo
KLAS NORRBY
1 and ARVID NORDENHEM
2
1Department of Pathology, University of Gothenburg, Gothenburg; and
2Biovitrum AB, Stockholm, Sweden
Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis medi-
ated by heparin-binding VEGF-A in vivo. APMIS 2010; 118: 949–57.
Tumors are angiogenesis dependent and vascular endothelial growth factor-A (VEGF-A), a heparin-
binding protein, is a key angiogenic factor. As chemotherapy and co-treatment with anticoagulant
low-molecular-weight heparin (LMWH) are common in cancer patients, we investigated whether
angiogenesis in vivo mediated by VEGF-A is modulated by metronomic-type treatment with: (i) the
LMWH dalteparin; (ii) low-dosage cytostatic epirubicin; or (iii) a combination of these two drugs.
Using the quantitative rat mesentery angiogenesis assay, in which angiogenesis was induced by
intraperitoneal injection of very low doses of VEGF, dalteparin sodium (Fragmin
 ) and epirubicin
(Farmorubicin
 ) were administered separately or in combination by continuous subcutaneous infu-
sion at a constant rate for 14 consecutive days. Dalteparin was administered at 27, 80, or
240 IU⁄kg⁄day, i.e., doses that reﬂect the clinical usage of this drug, while epirubicin was given at
the well-tolerated dosage of 0.4 mg⁄kg⁄day. While dalteparin signiﬁcantly stimulated angiogenesis in
an inversely dose-dependent manner, epirubicin did not signiﬁcantly aﬀect angiogenesis. However,
concurrent treatment with dalteparin and epirubicin signiﬁcantly inhibited angiogenesis. The eﬀect of
dalteparin is the ﬁrst demonstration of a proangiogenic eﬀect of any LMWH in vivo. The fact that
co-treatment with dalteparin and epirubicin signiﬁcantly inhibited angiogenesis suggests a complex
drug eﬀect.
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Tumor growth is angiogenesis dependent.
Heparin-binding vascular endothelial growth
factor-A (VEGF-A; VEGF) is a key angiogenic
factor in hypoxia, wound healing, inﬂamma-
tion, and tumor development (1). VEGF also
appears to be a mediator of angiogenic path-
ways involving other proangiogenic factors. The
most potent endogenous pro- and anti-
angiogenic proteins bind heparin and are depen-
dent upon heparan sulfate for their biologic
activities, while several enzymes and extracellu-
lar proteins bind heparin (2). Systemic heparin
treatment may aﬀect these proteins and
enzymes, blood cells and other circulating cells,
as well as vascular endothelial cells (ECs).
As tumor cells possess the capacity to interact
with the hemostatic system, patients with cancer
experience hypercoagulability with increased Received 18 December 2009. Accepted 19 April 2010
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thromboembolism, which requires anticoagu-
lant therapy. In clinical trials, cancer patients
undergoing surgery or suﬀering from acute
thrombosis and receiving conventional chemo-
therapy in combination with s.c. administra-
tion of various low-molecular-weight heparins
(LMWHs) display signiﬁcantly improved sur-
vival times, as compared with patients who are
treated either subcutaneously with unfractionat-
ed heparin (UFH) or orally with the anticoagu-
lant warfarin, or those who do not receive any
anticoagulant treatment (3–9). Extended sur-
vival is the most rigorous clinical benchmark for
cancer drugs. The fact that LMWHs exert prob-
ably multiple anti-cancer activities that are basi-
cally unrelated to their anticoagulant activity
attracts increasing interest as the basis for
improved survival times in patients with cancer
(2–6, 10). However, deﬁnitive conclusions
regarding the true anti-neoplastic eﬀects of
LMWHs cannot be drawn from the data of clin-
ical trials given the current methodologic limita-
tions.
The marketed anticoagulant LMWHs repre-
sent a diverse group of depolymerized heparin
preparations, with mean molecular weight
(MW) ranging from 2 to 9 kDa, although they
are usually in the approximately 6 kDa range
(11). Dalteparin has a MW of 6 kDa. Most
LMWHs are isolated from UFH (MW
15 kDa). Depending on the manufacturing
processes used, the LMWHs show structural,
biochemical, and pharmacologic diﬀerences,
and their behaviors show dependencies on dos-
age and route of administration (12, 13). Regu-
latory agencies, such as the European Medicines
Agency and the U.S. Food and Drug Adminis-
tration, consider the LMWHs to be distinct
pharmacologic agents and recommend that they
should not be regarded as being interchangeable
(14, 15). However, the pharmacologic diﬀer-
ences between these agents do not produce clini-
cally important diﬀerences in the outcomes of
anti-coagulation therapy in patients with venous
thromboembolism (14).
Metronomic chemotherapy, which is charac-
terized by continuous or frequent treatment
with cytotoxic agents at low and well-tolerated
dosages, has for many drugs been shown in pre-
clinical studies to exert potent anti-angiogenic
eﬀects and improved anti-tumor eﬀects without
important toxic side eﬀects, as compared with
conventional chemotherapy given at high doses
at intervals of typically 2–4 weeks (16, 17).
Somewhat similar beneﬁcial results are reported
concerning metronomic chemotherapy in
patients with common types of cancer (18–21).
Continuous infusion, as used in the present
study, can be viewed as an extended form of
metronomic treatment (22). The primary target
of metronomic chemotherapy is the angiogeni-
cally activated, proliferating normal EC in the
tumor vasculature. The activated EC is genomi-
cally stable, and therefore, is endowed with a
considerably lower risk of mutation and subse-
quent development of drug resistance than ge-
nomically unstable neoplastic cells. In addition
to exerting a direct anti-proliferative eﬀect on
angiogenically activated ECs, some chemother-
apeutics induce the expression of the potent
endogenous anti-angiogenic factor thrombo-
spondin in ECs cells in vitro (23) and tumors
in vivo (24).
The aim of the present study was to elucidate
whether metronomic-like treatment, i.e., contin-
uous s.c. infusion, with the dalteparin alone; the
chemotherapeutic agent epirubicin alone at a
low, virtually non-toxic dose; or these two drugs
in combination modulates VEGF-mediated
angiogenesis in vivo.
MATERIALS AND METHODS
Animals
Adult male Sprague–Dawley rats (B & K Universal,
Sollentuna, Sweden) were acclimatized to a standard-
ized environment for at least 7 days, fed ad libitum
and randomly allocated to weight-matched groups
with two animals housed per cage (25). At the start of
the experiments, when the animals were 6–7 weeks
old, the mean body weights in diﬀerent experiments
ranged from 218 to 223 g. Body weight was moni-
tored daily. The controls increased in weight by
approximately 55 g per week. Given the prompt phys-
iologic growth, drug-related weight-gain retardation
is a sensitive surrogate evaluation of toxicity, which
also includes systemic well-being, anorexia and failure
to thrive. Gauging body weight gain during chemo-
therapy is important, as low toxicity, which allows
long-term continuous or frequent treatment, is inher-
ent to metronomic scheduling. Moreover, toxic eﬀects
diminish analysis sensitivity. The local Animal Ethics
Committee approved this study. The ethical
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Angiogenesis induction and a note on the mesentery
assay
Rat rVEGF164 (564-RV⁄CF; R&D Systems Europe,
Ltd., Oxon, UK), which is the predominant VEGF-A
isoform in rats, was diluted to 96 pmol⁄mL in endo-
toxin-free saline used for infusion into patients, fro-
zen and thawed, and a volume of 5 mL was injected
i.p. into the rats (27). This treatment, given twice daily
for 4.5 days, i.e., from Monday morning (Day 0) to
Friday morning (Day 4), induces a vigorous angio-
genic response in the mesenteric test tissues, peaking
around Day 21 (27). The VEGF does not aﬀect body
weight gain. It was within this time frame of micro-
vessel network proliferation that the s.c. treatments
with dalteparin and epirubicin were given.
Similar to most normal adult tissues, the test tissue
used, i.e., the membranous, small-gut mesentery in
rats is natively vascularized (albeit sparsely) and lacks
signiﬁcant physiologic angiogenesis due to equilib-
rium between pro- and anti-angiogenic inﬂuences (28,
29). The test tissue is untouched mechanically until
the experiment is concluded. The inﬂammatory stim-
ulus of the test tissue is minimal, if any, ensuring a
high level of sensitivity, because inﬂammation induces
angiogenesis (28). This model compares well with
other in vivo angiogenesis models, as discussed else-
where, and allows true quantiﬁcation of unbiased
variables (28, 29). Importantly, the rat mesenteric
assay replicates the clinical situation, as the test drugs
are administered systemically and the responses
observed reﬂect the net eﬀect of all the metabolic,
cellular, and molecular alterations induced by the
treatment.
Continuous subcutaneous infusion of dalteparin and
epirubicin for 14 days
Filling and implanting of osmotic minipumps – On
Day )2, i.e., 2 days before the start of the angiogenic
i.p. VEGF treatment, osmotic minipumps (Model
2002 for dalteparin and Model 2ML2 for epirubicin,
with constant pumping rates of 0.5 and 5.0 lL⁄h for
14–15 days, respectively; Alzet
  Osmotic Pumps,
Mountain View, CA, USA) were ﬁlled under sterile
conditions with the test solution or its vehicle. One
day later (Day )1), after being stored in sterile 0.9%
(w⁄v) NaCl overnight at 37  C, the pumps were sur-
gically implanted s.c. on the backs of rats that had
been anesthetized with inhaled isoﬂurane (Forene
 ,
Abbott, Abbott Park, IL, USA). The skin incision,
made for pump implantation, was immediately
sutured post-implantation. As only minute volumes
were infused at a low rate, it is highly improbable
that pH in the mesentery microvessels was aﬀected to
any measurable degree by the diﬀerence in vehicle pH
for dalteparin and epirubicin. As the animals sub-
stantially gained weight physiologically during the
experimental period (Table 1), the actual dose per kg
body weight was somewhat above the average dosage
at the beginning of the infusion period and somewhat
below the average dosage at the end of the infusion
period.
Dalteparin monotherapy – A dose–eﬀect study of
continuously infused dalteparin at 27, 80, and
240 IU⁄kg⁄day, which is within the dose range used
in patients, on VEGF-mediated angiogenesis was
performed (Table 2). The vehicle saline (pH 7) is used
for infusion into patients. Dalteparin at 80 IU⁄kg⁄
day (Fragmin
 , Pﬁzer, New York, NY, USA; mean
molecular weight range 5.6–6.4 kDa, with MW of
Table 1. Eﬀect on physiologic body weight gain of continuous subcutaneous epirubicin infusion for 14 consecu-
tive days
Body weight, g
Day Vehicle control Epirubicin, mg⁄kg⁄week
1.5 3.0 6.0
Percentage of vehicle control
0 225.0 ± 2.6 222.3 ± 2.5 225.0 ± 2.2 218.5 ± 3.4
100 99 100 97
6 275.0 ± 4.2 271.7 ± 3.4 268.2 ± 2.0 255.3 ± 2.3
100 99 98 93
9 297.3 ± 5.0 287.2 ± 3.6 289.0 ± 3.2 272.0 ± 2.7
100 97 97 91
14 334.2 ± 5.6 318.3 ± 4.9 314.8 ± 4.4 291.7 ± 2.9
100 95 94 87
Each treatment group comprised six animals. The vehicle was 0.9% NaCl. The vehicle control was set at 100%.
Data shown are mean ± SEM.
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unit) was infused (Table 2). Vehicle controls were
included.
Epirubicin monotherapy – In an initial dose-ﬁnding
experiment, epirubicin, which is of the anthracycline
class of intercalating topoisomerase-targeting agents
(30), was infused at doses of 1.5, 3.0, and
6.0 mg⁄kg⁄week. The drug was diluted in 0.9% (w⁄v)
NaCl (pH 4.5), used for infusion into patients. Vehi-
cle controls were infused in a similar fashion. The
intention was to ﬁnd a well-tolerated dose that would
only marginally diminish the weight gain, as com-
pared with the rapidly growing vehicle controls
(Table 1). In the subsequent angiogenesis experi-
ments, epirubicin at 3.0 mg⁄kg⁄week was used. It has
been claimed that the dosage per body surface area
(mg⁄m
2) may be useful in comparing drug toxicities
between species (i.e., between laboratory animals and
humans). For a rat that weighs 250 g, the dosage in
mg⁄kg multiplied by 7 yields the approximate dosage
in mg⁄m
2. Thus, the dose used in the angiogenesis
experiment corresponds to 21 mg⁄m
2 per week in a
human.
Dalteparin and epirubicin co-treatment – The ani-
mals were infused with epirubicin at 3.0 mg⁄kg⁄week
and dalteparin at 80 IU⁄kg⁄day or vehicle, using two
minipumps per animal (Table 3).
Angiogenesis quantiﬁcation
After 14 days of treatment, four membranous, virtu-
ally transparent (window-like) samples from the most
distal part of the small-gut mesentery, immediately
Table 2. Eﬀect of 14 days of subcutaneous continuous infusion of dalteparin alone, epirubicin alone, and a com-
bination of the two drugs on VEGF-mediated angiogenesis and body weight (BW) at sacriﬁce
Vehicle⁄D + Vehicle⁄E
2 Dalteparin
1 + Vehicle⁄D
2 Epirubicin
1 + Vehicle⁄E Dalteparin + Epirubicin
Group C I Group C II Group T I Group T II
BW, g 323.30 ± 6.20 (100) 322.00 ± 4.76 (100) 299.60 ± 4.94 (93) 301.40 ± 5.59 (93)
VA
3 14.55 ± 2.36 (100) 18.47 ± 2.89 (127) 14.68 ± 2.00 (101) 13.25 ± 2.20 (91)
MVL 1.12 ± 0.08 (100) 1.15 ± 0.07 (103) 0.98 ± 0.08 (88) 0.88 ± 0.06* (79)
TMVL 16.28 ± 2.64 (100) 21.28 ± 3.33 (131) 14.39 ± 1.96 (88) 11.64 ± 1.94** (71)
Values within parenthesis are % of value for CI.
1Dalteparin at 80 IU⁄kg⁄day; epirubicin at 3.0 mg⁄kg⁄week.
2Vehicle⁄D, 0.9% NaCl; Vehicle⁄E, 0.9% NaCl. Each treatment group comprised 10 animals, with the exception
of group T II, which comprised nine animals (one rat was removed due to signs of sickness). There are no statisti-
cally signiﬁcant diﬀerences with respect to any variable between groups T I and T II or between groups C I and C
II. Data shown are mean ± SEM.
3VA, vascularized area, a measure of microvessel spatial extension; MVL, microvascular length, a composite
measurement of microvessel density; TMVL, total microvascular length (VA · MVL).
*p £ 0.02 compared with C II, p £ 0.01 compared with [C I + C II]; **p £ 0.04 compared with C II, p £ 0.05
compared with [C I + C II].
Table 3. Eﬀects on VEGF-mediated angiogenesis of continuously infused dalteparin administered subcutane-
ously at diﬀerent doses for 14 consecutive days
Dalteparin IU⁄kg⁄day Angiogenesis variables
VA
1 MVL TMVL
Vehicle control (n = 12) 11.72 ± 2.66 (100) 0.901 ± 0.100 (100) 10.56 ± 2.40 (100)
27 (n = 12) 16.07 ± 2.67 (137) 1.126 ± 0.072** (125) 18.09 ± 3.00** (171)
80 (n = 11) 16.89 ± 3.82 (144) 1.064 ± 0.107 (118) 17.26 ± 3.90* (163)
240 (n = 9) 13.51 ± 1.93 (115) 0.872 ± 0.076*** (97) 11.78 ± 1.68 (112)
Values within parenthesis are percent of control.
1VA, a measurement of microvessel spatial extension; MVL, a composite measurement of microvessel density;
TMVL = (VA · MVL).
*p £ 0.10, **p £ 0.05 compared with vehicle (0.9% NaCl) control; ***p £ 0.05 compared with the low dose of
27 IU⁄kg⁄day. Data shown are mean ± SEM. n = number of animals.
On Day 10 of the 14-day treatment, one animal in the 80 IU⁄kg⁄day group and three animals in the 240 IU⁄kg⁄
day group developed s.c. blood-streaked liquid accumulation at the site of the osmotic infusion pump and were
therefore sacriﬁced. These animals are excluded from the analysis.
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scopically after being spread intact on objective slides
and stained immunohistochemically (27). Normally,
this tissue is only 5- to 10-lm thick in its avascular
parts, making the whole microvessel network virtu-
ally two-dimensional, which is the basis for the
unique ability to quantify microvessel variables in the
intact tissue. The surrounding fatty tissue distinctly
delineated each window. The entire vasculature of
each of the four mesenteric windows per animal was
visualized using a primary monoclonal antibody
against rat endothelium, MRC OX-43 (31), which
labels the vascular endothelium in all tissues of the
rat, except that of the brain capillaries. This proce-
dure allows the straightforward identiﬁcation of even
the smallest microvessels.
For the analysis of unbiased microvessel variables,
microscopic morphometry and computerized image
analysis were employed in a blinded fashion. Objec-
tive variables are a prerequisite for strict dose–
response analysis. First, the total area of each
mesenteric window was measured. The following
variables were then measured in each window (27):
the percentage vascularized area (VA), which is
a measurement of the spatial extension of the net-
work; and microvascular length (MVL), which is a
composite measurement of microvessel density. The
total microvascular length (TMVL) was calculated
as TMVL = VA multiplied by the mean MVL⁄
treatment group.
Statistical analysis
The non-parametric Mann–Whitney U-test for un-
paired (two-tailed) observations was used. A mean of
four windows per animal was used as independent
data for each variable in the mesenteric window. The
criterion for statistical signiﬁcance was p £ 0.05.
RESULTS
Eﬀect on physiologic body weight gain of dalteparin
and epirubicin treatment
Continuous infusion of dalteparin at 27, 80, and
240 IU⁄kg⁄day for 14 days did not aﬀect body
weight gain compared with vehicle controls
(data not shown). The eﬀects of the continuous
infusion of epirubicin at 1.5, 3.0, and
6.0 mg⁄kg⁄week are shown in Table 1. Based
on previous experience (27, 28), we concluded
that epirubicin at 3.0 mg⁄kg⁄week, which
reduced body weight by only 6% at sacriﬁce
compared with the rapidly growing vehicle-trea-
ted controls, was the appropriate dosage.
Eﬀects on VEGF-mediated angiogenesis of continuous
infusion of dalteparin alone, epirubicin alone, and
co-treatment of dalteparin and epirubicin
Treatment with dalteparin (80 IU⁄kg⁄day)
+ vehicle (group C II), using two s.c. pumps
per animal, increased overall angiogenesis
TMVL by 31%, as compared with the controls
that were treated with vehicle + vehicle (group
C I) using two s.c. pumps (Table 2). However,
this diﬀerence was statistically non-signiﬁcant.
Treatment with epirubicin + vehicle (group
T I) reduced the TMVL by 12%, as compared
with the vehicle + vehicle control (group C I),
although this diﬀerence was also non-signiﬁ-
cant. Co-treatment with dalteparin + epirubi-
cin (group T II) reduced the MVL by 24%
(p £ 0.02) and TMVL by 45% (p £ 0.04), as
compared with the controls that received daltep-
arin + vehicle (group C II). Furthermore,
treatment with dalteparin + epirubicin (group
T II) signiﬁcantly reduced both the MVL and
TMVL, as compared with the extended control
group (vehicle + vehicle and daltepa-
rin + vehicle, i.e., groups C I and C II), as
shown in Table 2.
As the infusion of dalteparin (80 IU⁄kg⁄day)
+ vehicle for 14 days increased the TMVL by
31%, compared with the vehicle + vehicle con-
trols (Table 2), we performed a dose–eﬀect
study, in which we infused dalteparin continu-
ously for 14 days at 27, 80, and 240 IU⁄kg⁄day
(Table 3). The lowest dose, 27 IU⁄kg⁄day,
increased the VA by 37%, MVL by 25%, and
TMVL by 71% (p £ 0.05), compared with the
corresponding values for the vehicle control.
The highest dosage, 240 IU⁄kg⁄day, had only
a marginal eﬀect on angiogenesis, while
80 IU⁄kg⁄day exerted intermediate eﬀects on
the VA (+44%), MVL (+18%), and TMVL
(+63%). It is noteworthy that the eﬀect of dal-
teparin on MVL was signiﬁcantly dose depen-
dent (Table 3).
DISCUSSION
The present study demonstrating that daltepa-
rin (MW, 6 kDa) stimulates VEGF-mediated
angiogenesis is to the best of our knowledge the
ﬁrst report of a proangiogenic eﬀect of any
LMWH in vivo (2). By contrast, a 5-kDa
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 ,
LEO Pharma, Copenhagen, Denmark) has been
shown to inhibit VEGF-induced angiogenesis
in vivo using the same experimental system (2,
25). As dalteparin and tinzaparin display similar
degrees of sulfation and the diﬀerence in MW
(6 kDa vs 5 kDa) is small, it appears that the
particular type of LMWH rather than the mean
molecular weight is decisive for the outcome in
the angiogenesis model used. This is important
because the anti-angiogenic eﬀect of tinzaparin
is dependent on molecular size (25). While dal-
teparin is produced by nitrous acid depolymer-
ization of porcine gut mucosal UFH, which
results in the formation of anhydromannose (a
ﬁve-member ring) in the molecule, tinzaparin is
produced by controlled enzymatic depolymer-
ization by heparinase digestion of porcine gut
mucosal UFH, which adds a double bond to the
end group of the molecule (12, 15, 32). Interest-
ingly, heparin fragments in the 4.8–5.4 kDa
range, produced from porcine gut mucosa UFH
after being dissolved in buﬀer and exposed to
chromatography on a sephadex column, inhibit
the binding of
125I-VEGF to the VEGF recep-
tors on cultured ECs (33).
As tumor growth is angiogenesis dependent, it
is of interest to assess the anti-angiogenic eﬀects
of candidate anti-tumor drugs. However, there
are no ways to accurately assess the anti-angio-
genic eﬀect per se of drugs on tumors because
inhibition of angiogenesis limits tumor growth
and vice versa (28, 34, 35). The true anti-angio-
genic eﬀect of any treatment must therefore be
assessed in a surrogate non-tumor tissue. As
VEGF is a key proangiogenic factor in most
human and experimental tumors (1), VEGF-
mediated angiogenesis would be an appropriate
surrogate model for tumor angiogenesis, espe-
cially because the ECs in tumor angiogenesis
use the same signaling pathways as the ECs
involved in non-tumor angiogenesis (36).
However, the present assay does not take into
account all the aspects of tumor-induced angio-
genesis, such as the presence of multiple proangi-
ogenic factors that usually operate in advanced
cancers (37) or the chaotic microvessel patterns
and perfusion of tumor vasculature observed
predominantly in the central parts of tumors.
Nevertheless, the present assay for VEGF-medi-
ated angiogenesis has demonstrated a close cor-
relation between the anti-angiogenic eﬀects in
the tumor-free mesentery on one hand and the
anti-tumor and indirectly assessed anti-angio-
genic eﬀects in the tumors on the other hand
after continuous paclitaxel infusion in a rat
model of syngeneic prostate cancer (38). Addi-
tional corroboration that inhibition of VEGF-
induced angiogenesis in the tumor-free mesen-
tery may reﬂect signiﬁcant events leading to inhi-
bition of tumor growth comes from the fact that
systemic treatment with bovine iron-unsaturated
lactoferrin suppresses VEGF-induced angio-
genesis inthe ratmesentery model (39), aswell as
cancer cell-induced angiogenesis in a mouse dor-
sal air sac assay (40). Compared with other non-
tumor angiogenesis assays, the present assay
standsoutasapparentlysuperiorintermsofbio-
logic relevance and ability to objectively quan-
tify pertinent angiogenesis variables (28, 29).
The fact that the continuous treatment
with (dalteparin + epirubicin) inhibited angio-
genesis signiﬁcantly as compared with (dal-
teparin + vehicle) or (epirubicin + vehicle)
treatment is indeed interesting in view of the
improved survival time of cancer patients who
receive co-treatment of dalteparin and other
LMWHs with conventional chemotherapy (3–8,
10). As is true for heparins in general, dalteparin
is able to bind, release, and inﬂuence the actions
of heparin-binding proteins, such as proangio-
genic growth factors (e.g., VEGF and basic
ﬁbroblast growth factor), anti-angiogenic
factors (e.g., thrombospondin), enzymes (e.g.,
heparanase), and extracellular matrix proteins
that may signiﬁcantly inﬂuence angiogenesis (2,
12, 41, 42). Moreover, heparins inﬂuence a
number of additional angiogenesis-modulating
factors, such as P- and L-selectins, integrins,
platelets and all other circulating cells, circulat-
ing microparticles (derived from ECs and leuko-
cytes), antioxidant function, and release tissue
factor pathway inhibitor (TFPI-1). TFPI-1,
which is mainly synthesized in and localized to
ECs, is the natural inhibitor of tissue factor,
which is a critical promoter of angiogenesis. It
is noteworthy that diﬀerent LMWHs exhibit
major diﬀerences in their abilities to release
TFPI from the vascular lining (43), the highest
release occurring following treatment with
tinzaparin (10, 43). Not surprisingly, TFPI-1
released by 6–8 kDa tinzaparin fractions sup-
presses angiogenesis in the embryonic chick
chorioallantoic membrane assay (44).
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experimental system, low concentrations of
exogenous antioxidants play a decisive role in
the angiogenesis-modulating eﬀects of certain
cytotoxic agents that are infused continu-
ously at low doses (31, 45). Thus, ﬂuorouracil,
cisplatin, and paclitaxel signiﬁcantly inhibit
VEGF-mediated angiogenesis when the vehicle
displays antioxidant activity or in the case
of co-treatment with a potent antioxidant,
whereas these cytotoxics show no anti-angio-
genic eﬀects when the vehicle lacks an antioxi-
dant. By contrast, continuous low-dosage
infusion of doxorubicin, which is an epimer
(one of two molecules that diﬀer only in the
spatial arrangement around a single carbon
atom) of epirubicin, does not aﬀect VEGF-
mediated angiogenesis even when combined
with an antioxidant (31). Therefore, the anti-
angiogenic eﬀects by the concurrent treatment
with dalteparin and epirubicin (Table 2) are
probably not dependent on antioxidant activity
of dalteparin. Some additional, as yet
unknown, feature of dalteparin appears to play
an important role in the anti-angiogenic action.
The fact that (dalteparin + epirubicin) signiﬁ-
cantly inhibited angiogenesis, while the individ-
ual drugs at the doses given did not inﬂuence
angiogenesis, is in line with results obtained for
mice bearing the human U87 glioblastoma
xenograft: in these mice, tumor growth was
unaﬀected by daily s.c. injections of dalteparin
alone or only moderately aﬀected by SU5416
alone, whereas the co-treatment of dalteparin
and SU5416 signiﬁcantly decreased the level of
VEGF in the tumors and strongly inhibited
tumor growth (46). SU5416 is a small molecule
inhibitor of tyrosine kinase receptors, including
the VEGF receptors.
As it is not known which of the marketed
LMWHs exerts the most potent anti-neoplastic
eﬀect in cancer patients receiving chemotherapy,
be it conventional or metronomic, bona ﬁde
prospective clinical trials comparing directly the
eﬀects of two or more LMWHs on survival time
and disease progression are warranted.
The proangiogenic eﬀect of dalteparin in the
present report should be beneﬁcial for the treat-
ment of non-cancer patients with poor periph-
eral circulation or thromboembolism causing
tissue hypoxia, which induces compensatory
VEGF-mediated angiogenesis. The present
ﬁndings actually appear to ﬁt the available clini-
cal data in this respect. It is of note that daily
s.c. injections of dalteparin for up to 6 months
(5,000 IU, corresponding to 60–70 IU⁄kg⁄
day) signiﬁcantly improve the outcomes for
chronic foot ulcers in diabetic patients with
peripheral arterial occlusive disease (47). Fur-
thermore, it has been hypothesized that daltepa-
rin, which appears to improve the capillary
circulation in the foot ulcer margin, could have
a proangiogenic eﬀect in these patients (48).
Moreover, in patients with stable coronary artery
disease, exercise in combination with dalteparin
reduces myocardial ischemia, possibly as a
result of enhanced collateral function (49).
The Swedish Medical Research Council (5249) and
Pﬁzer Sweden AB provided ﬁnancial support for this
study. During this study, Dr. Nordenhem was
employed by Pﬁzer Sweden AB.
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